THTX vs. TYRA, PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, BCYC, and BCAX
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Tyra Biosciences (TYRA), Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), Bicycle Therapeutics (BCYC), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs. Its Competitors
Tyra Biosciences (NASDAQ:TYRA) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.
Tyra Biosciences has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Theratechnologies' return on equity of 0.00% beat Tyra Biosciences' return on equity.
Tyra Biosciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
In the previous week, Tyra Biosciences had 1 more articles in the media than Theratechnologies. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 1.78 beat Tyra Biosciences' score of 0.62 indicating that Theratechnologies is being referred to more favorably in the news media.
Theratechnologies has higher revenue and earnings than Tyra Biosciences. Theratechnologies is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences currently has a consensus price target of $30.83, indicating a potential upside of 178.78%. Given Tyra Biosciences' higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Theratechnologies.
84.1% of Tyra Biosciences shares are owned by institutional investors. 15.2% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Tyra Biosciences beats Theratechnologies on 8 of the 15 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 7/25/2025 by MarketBeat.com Staff